Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Grows By 470.4%

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totaling 113,911 shares, an increase of 470.4% from the June 15th total of 19,972 shares. Approximately 4.5% of the company’s stock are sold short. Based on an average daily trading volume, of 157,314 shares, the short-interest ratio is currently 0.7 days.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs as of its most recent SEC filing. 8.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

VivoSim Labs Price Performance

Shares of VivoSim Labs stock traded down $0.07 during trading on Monday, hitting $0.81. 122,145 shares of the company’s stock traded hands, compared to its average volume of 823,231. VivoSim Labs has a 1 year low of $0.78 and a 1 year high of $5.30. The business has a 50-day simple moving average of $1.19 and a 200-day simple moving average of $1.63. The stock has a market capitalization of $2.11 million, a P/E ratio of -0.26 and a beta of 1.40.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.